Aprea Therapeutics, Inc. (APRE)
0.8052
+0.16
(+25.75%)
USD |
NASDAQ |
Aug 24, 16:00
0.75
-0.06
(-6.86%)
After-Hours: 20:00
Aprea Therapeutics Enterprise Value : -30.53M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | -30.53M |
| August 21, 2026 | -32.57M |
| August 20, 2026 | -32.58M |
| August 19, 2026 | -32.19M |
| August 18, 2026 | -32.18M |
| August 17, 2026 | -31.96M |
| August 14, 2026 | -32.08M |
| August 13, 2026 | -32.19M |
| August 12, 2026 | -32.04M |
| August 11, 2026 | -32.33M |
| August 10, 2026 | -32.52M |
| August 07, 2026 | -32.45M |
| August 06, 2026 | -32.67M |
| August 05, 2026 | -32.81M |
| August 04, 2026 | -33.08M |
| August 03, 2026 | -33.10M |
| July 31, 2026 | -32.82M |
| July 30, 2026 | -32.64M |
| July 29, 2026 | -32.81M |
| July 28, 2026 | -32.90M |
| July 27, 2026 | -32.77M |
| July 24, 2026 | -32.67M |
| July 23, 2026 | -32.69M |
| July 22, 2026 | -32.33M |
| July 21, 2026 | -32.43M |
| Date | Value |
|---|---|
| July 20, 2026 | -32.22M |
| July 17, 2026 | -31.71M |
| July 16, 2026 | -31.96M |
| July 15, 2026 | -31.86M |
| July 14, 2026 | -31.48M |
| July 13, 2026 | -31.56M |
| July 10, 2026 | -31.27M |
| July 09, 2026 | -31.49M |
| July 08, 2026 | -31.31M |
| July 07, 2026 | -30.97M |
| July 06, 2026 | -31.21M |
| July 02, 2026 | -31.32M |
| July 01, 2026 | -31.27M |
| June 30, 2026 | -30.56M |
| June 29, 2026 | -35.92M |
| June 26, 2026 | -36.27M |
| June 25, 2026 | -36.27M |
| June 24, 2026 | -36.05M |
| June 23, 2026 | -35.82M |
| June 22, 2026 | -36.23M |
| June 18, 2026 | -37.17M |
| June 17, 2026 | -36.39M |
| June 16, 2026 | -37.00M |
| June 15, 2026 | -37.37M |
| June 12, 2026 | -37.52M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Zymeworks, Inc. | 2.068B |
| Rhythm Pharmaceuticals, Inc. | 7.562B |
| Onconetix, Inc. | -3.265M |
| ACADIA Pharmaceuticals, Inc. | 4.221B |
| Alnylam Pharmaceuticals, Inc. | 31.24B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.591M |
| Total Expenses (Quarterly) | 3.591M |
| EPS Diluted (Quarterly) | -0.0671 |
| Earnings Yield | -133.7% |
| Normalized Earnings Yield | -133.74 |